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Background: The aim of this study was to compare the efﬁcacy and safety of
everolimus-eluting stents (EES) in treatment of patient with coronary artery disease
(CAD) as compared to other drug eluting stents (DES): paclitaxel eluting stents (PES),
sirolimus eluting stents (SES), zotarolimus eluting stents (ZES) and biolimus A9
eluting stents (BES).
Methods: Katowice Registry included 1916 consecutive patients treated with EES
as well as non-EES group (PES, SES, ZES, BES). Primary efﬁcacy end-point was
Major Adverse Cardiac and Cerebrovascular event (MACCE) deﬁned as death,
stroke or repeat-revascularization at 1-year follow-up. Safety end-point was stent
thrombosis.
Results: Registry included [UA 1502 (78%), NSTEMI 238 (15%), STEMI
131(7%)]. There were 770 (35%) patients in EES group and 1246 (65%) in non-EES
group. There were no differences in the prevalence of diabetes (36% vs. 38%
p¼0.47), chronic kidney disease (18% vs. 17% p¼0.32) as well as complexity of
CAD measured by SYNTAX [SX] score between EES and non-EES. Use of EES
group was comparable to non-EES in terms of risk of death [HR¼0.82 (95%CI
0.48–1.40), p¼0.55), myocardial infarction [HR¼0.75 (95%CI 0.47–1.19), p¼0.26],
target vessel revascularization [HR¼0.90 (95%CI 0.46–1.26), p¼0.58], stroke
[HR¼0.51 (95%CI, 0.14–1.81), p¼0.43] or MACCE [HR¼0.80 (95%CI, 0.60–
1.06), p¼0.28] at 1-year follow-up. Use of EES was associated with lower rate of
acute as wel as subacute stent thrombosis than non-EES [0% vs. 0.6 and 0% vs.
0.2%, respectively, p¼0.02).
Conclusions: Nonrestricted use of EES was associated with lower rate of early ST as
compared to other DES. The 1-year incidence of MACCE was similar in EES in
comparison to other DES.
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Background: aim of this study was to evaluate the sex differences in the long-term
clinical outcomes and safety of patients treated with ﬁrst- and second generation DES.
Methods: The Katowice-Zabrze Registry included 1916 consecutive patients treated
with either ﬁrst- (paclitaxel, sirolimus eluting; 34%) or second-generation (everolimus,
zotarolimus, biolimus A9, 66%) DES. Primary efﬁcacy end-point was Major Adverse
Cardiac and Cerebrovascular event (MACCE) deﬁned as death, stroke or repeat-
revascularization were recorded at 1-year follow-up. Safety endpoint was stent
thrombosis.
Results: Registry included [UA 1502 (78%), NSTEMI 238(15%), STEMI 131 (7%)].
There were 680 (35.5%) females and 1236 (64.5%) males. Women were older
(65.99.8 vs. 61.89.8 years, p< 0.001) and had higher prevalence of diabetes
(50.1% vs. 30.4%, p< 0.001) and chronic kidney disease (24.7% vs. 13.2%, p<
0.001). Conversely, multivessel coronary artery disease was more frequent in males
(30.1% vs 21.9% p< 0.001). There were no differences in complexity of coronary
artery disease between males and female as measured by SYNTAX. There was no
difference in ratio of early stent thrombosis (0.5% vs 0.6%, p¼0.88) but women had
more often bleeding complications after PCI that required urgent blood transfusion
(1.7% vs. 0.4%, p¼0.005) and had longer hospitalization time (6 IQR 4-7 vs 5 IQR 3-
6 days p< 0.001). Univariable Cox regression analysis revealed that women had
similar outcome as men in terms of a risk of death [HR¼1.08 (95%CI 0.64–1.82),
p¼0.880), myocardial infarction [HR¼0.72 (95%CI 0.47–1.09), p¼0,149], target
vessel restenosis [HR¼1.05; (95%CI 0.75–1.46), p¼0.849],stroke [HR¼1.38 (95%JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteCI, 0.43–4.41), p¼0,792] and MACCE [HR¼0.97 (95%CI, 0.75–1.28), p¼0.977] at
1-year follow-up. There were no differences between sexes in MACCE when forst and
second generaton DES were analyzed separately.
Conclusions: Despite higher risk proﬁle, women treated with DES are not at increased
risk of death or MACCE as compared to men at 1-year follow-up. There is however an
increased risk of periprocedural bleeding complications in women.
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Background: The PE Plus Post-Approval Study (PE Plus PAS) was designed to
examine outcomes among patients treated with advanced generation, everolimus-
eluting, platinum chromium PROMUS Element stents (Boston Scientiﬁc, Natick,
MA) over 5 years in a ‘real-world setting’. This is the ﬁrst report of results from this
large multicenter post-approval study.
Methods: PE Plus PAS was a prospective, open-label, multicenter observational study
at 52 enrolling sites in the US. Follow-up was at 30 days, 6 months, and 1 year, and
will continue annually through 5 years. The primary endpoint was 12-month cardiac
death or myocardial infarction (CD/MI) in ‘PLATINUM-like’ patients pooled from
PE Plus PAS and PE PROVE and patients from the PLATINUM Workhorse (WH)/
Small Vessel (SV) trials. The PLATINUM-like patient cohort was deﬁned as all
patients that met the criteria for enrollment in the Platinum WH/SV trials. A 1-sided z-
approximation test was applied to determine if the 12-month CD/MI rate met the
prespeciﬁed performance goal of 3.2% (expected rate of 2.2% + delta of 1.0%). Rates
of major adverse cardiac events (MACE), the individual components of MACE as
well as ARC deﬁnite/probable stent thrombosis will be analyzed in the overall PE Plus
PAS patient population in addition to the prespeciﬁed Platinum-like group. Incidence
of longitudinal stent compression conﬁrmed by core laboratory assessment was also
assessed.
Results: Among 2684 enrolled patients, 70% were male, mean age was 6411 years,
37% had medically treated diabetes, and more than three-quarters were treated for
hyperlipidemia and hypertension. At baseline, mean lesion length among 3595 treated
lesions was 1710 mm and mean reference vessel diameter was 2.90.5 mm. Plat-
inum-like patients accounted for 29% of the overall PE Plus PAS patient population.
Conclusions: The primary endpoint results from the PE Plus PAS will be available at
the time of the presentation and will lend insight into the performance and safety of the
PROMUS Element Plus everolimus-eluting stent at 1 year in everyday clinical
practice.
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Background: Previous trials showed that, compared to 1st generation drug eluting
stent (DES), coronary artery by-pass surgery (CABG) signiﬁcantly reduces major
cardiac adverse events (MACCE) in patients (pts) with multiple vessel disease
(MVD).
Methods: Between March 2013 and January 2014 we included 225 pts undergoing
DES implantation in 15 sites in Argentina. The registry followed all regulatory process
and was monitored by an external independent committee. Primary endpoint of
ERACI 4 Registry was to assess the incidence of MACCE [death, myocardial
infarction (MI) cerebrovascular accident (CVA) and unplanned target vessel revas-
cularization (TVR)] in pts with MVD using Firebird-2 rapamycin eluted stents
(MicroPort, Shangai) vs. ERACI 3 population (1st generation DES and CABG arms)
at 30 days, 6 and 12 months of follow-up. All pts have an indication for myocardial
revascularization and lesions  70% in 2 or 3 coronary arteries and/or unprotected left
main disease (ULM). Exclusion criteria were ejection fraction  35%, recent STEMI
(< 72 hours), DES in an intention to treat artery, lesion diameter  2.5 mm or
contraindications for dual antiplatelet therapy (DAPT). Stent thrombosis was also
analyzed. The only DES allowed was Firebird-2.nts - Drug-eluting: Registries B167
